Abnormal urinary kallikrein excretion in patients with congestive heart failure  by Guarda, Eduardo et al.
318A ABSTRACTS SACC Vol. 17. No. 2 February 1991 :318A 
UNCOUPLING OF ATRIAL NATRIURETIC PEPTIDE EXTRACTION AND 
CYCLIC GUANOSINE MONOPHOSPHATE PRODUCTION IN PULMONARY 
CIRCULATION IN PATIENTS WITH SEVERE CONGESTIVE HEART 
FAILURE 
Takayoshi Tsutamoto, Toshiyuki Kanamori, Makoto Itoh, Masahiko Kmoshila. 
First Depanment of Internal Medicine, Shiga University of Medical Science, 01% 
Japan 
To evaluate the role of endogenous atrial natriuretic peptides (ANP) in pulmonary 
circulation, we determined plasma ANP and cyclic guanosine monophosphate 
(cGMP) levels in the main pulmonary artery (PA) and the pulmonary capillary 
wedge region (PC) of 70 patients with chmnic congestive heart failure (CHF). The 
plasma ANP level decreased significantly from the PA 10 the PC (236 5 34 pglml 
vs I84 + 22 pg/ml, ptO.OOl), whereas the plasma cGMP level increased 
significantly from the PA 10 the PC (6.2 & 0.4 pmol/ml vs 7.8 k OS pmollnrl, 
p<O 001). In patients with mild CHF (n=SO), the plasma ANP level correlated with 
the cGMP level (rz0.76, pcO.OOl), and the ANP extraction ratio (PA-PC/PA-ANP) 
correlated with the pulmonary vascular resistance (r=0.73, p<O.OOI) The ANP 
extnction level (AE): [(PA-PC) ANP X cardiac output (CO) X (I-H1/lOO)(ng/mm)] 
also correlated with the cGMP production level (GP): [(PC-PA) cGMP X CO x 
(I-HUlOO)(nmol/min)] (rz0.78, pcO.001). In cantfast, these correlations were not 
found in patients with severe CHF (n=20). In these patients, the AE level was 
significantly higher but then was no significant difference in Ihe GP level bc,ween 
the two groups. Therefon. the GP/AE molar ratio was significantly lower in 
patients with severe CHF (6600 ? IS00 vs 44900 + 5700, PQ001). 
Conclusion: 
These results indicate that there may exist down-regulation of ANP receptors 
coupled 10 guanylate cyclase in the pulr.onafy vascular beds of patients with severe 
CHF. 
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INHIBITING ANP 
Martine B. De Kock, Anne-Marie D’HondC, Jean-Marie Detry, 
University of Louvain Medical School, Brussels, Belgium 
Candotraxil (C) is a neutral endopeptidase inhibitor 
preventing the rapid breakdown of the atria1 natriuretic 
peptide (ANP). The expected beneficial hemodynamic 
effects of this compound were assessed at rest (R) and 
during exercise (Ex) in 12 stable Pts under chronic ACE 
inhibition for NYHA II-III congestive heart railure (CHF) 
in an acute double blind study. Measurements were made 
before and 4 hours after 200 mg of C (n=8) or a matched 
placebo (P) (n=4). Although elevated in the control(Ctr1) 
state pulmonary artery ANP level doubled (p<O.OOl) after 
C at R and during Ex (from 513 to A176 rig/ml (R) and from 
915 to 1436 rig/ml (Ex). Resulting hemodynamic changes 
(Table) were a significant fall in the right atria1 (RAP) 
and the pulmonary capillary wedge pressures (PCWP). Heart 
rate (HR),cardiac index (CI) and mean arterial pressure 
(MAP) were unaffected. No significant changes were noted 
after P. 
Table : PCWP RAP HR CI MAP 
mHf3 =J-Q3 bm l/min/m2 mHts 
c PC P c P c P c P 
R Ctrl 23 22 9 11 89 98 2.4 2.5 92 100 
R Drug 14* 22 6* 16 89 83 2.8 2.9 85 97 
Ex Ctrl 27 31 11 15 133 128 4.4 4.6 110 113 
Ex Drug 17* 26 8* 18 135 125 4.6 5.0 103 106 
(* p<O.Ol Ctrl vs Drug) 
Thus, by increasing circulating ANP levels C provides an 
additional benefit in controlling filling pressures at R 
and during Ex in CHF Pts treated with ACE-inhibition. 
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The renal ).allil:rein-klnln system (RCXS) 15 one 
of the several mechanlsmc that regulate sodlurn 
and water excretion. The involvement of the 
fit33 and its relationship to other regulatory 
mechan ismsb such as the renin-anglotensin and 
adrenergic nervou5 systems, in patients with 
CHF renlain to be elucidated. Accordingly, we 
determlned urinary kallikrein excretion (UK. 
U/24 hr, amldase method 1, treat inine clearance 
(CrCl, ml/24 hr), plasma renin activity (F'RA, 
n~/ml/h) and plasma noradrenaline concentration 
(NF1D, pg/ml) in 10 normal individuals (group 
FI). 11 patlents with stabie CHF, functior.al 
NYHfi class II a?d III (group B) and 6 patients 
watt. decompensated CHF. NVHk class IV (group 
Cl. We found (mean f: SEMI: 
Group FI Group E Group C 
ut’ 112s f. :Pb 677 ? 11418 136 r' 38 
CrCl 135 + 4 90 +- 9 4s + 5 
PRCI 0.8 ?: 0.1 t 3.3 + 0.7 7.2 + 2.0 
NAD 390 + 69 489 + 51 660 1(: 179 
11 = p c:C).Oi group A vs groups B and C 
t*= p 40.01 Group B vs C 
UK values, however, dxd not correlate wit11 CrCl 
nor with plasma NAD or PRCI. 
UC: fell progressively according to the sever-lty 
of CHF . Therefore, decreased LIti: tubular 
secretion may contribute to further altered Na 
and water halance in CHF. 
HEMODYNAMIC ACI’IONS OF ENDOTHELIN IN A LOW 
ATRIAL NATRIURETIC FACI’OR MODEL OF HEART FAILUhE 
R&IkntJJa, Lawrence L. Aarhus, John C. Burnett, Jr.; Mayo 
Clinic, Rochester, MN 
Endothelin (ET) is a recently described potent systemic and renal 
vasoconsuictor of endothelial origin. We recently reported ir !ack rf 
significant vasownstrictor response to pathophysiologic concentrations 
of ET in a high atrial natriuretic factor (ANF)-low cardiac output model 
of heart failure @IF). Moreover, recent studies in vivo and in vitro have 
shown ANF to attenuate the actions of ET. The current studv was 
thenfore designed to test the hypothesis that in a low ANF&w CO 
model of heart failure, achieved by thoracic inferior vena caval 
constriction mVCC), the systemic and renal vasoconstrictor esponses 
to ET are preserved. Eight days after surgery, TIVCC (n=S) vs SHAM 
(n=4), dogs were studied. ET-1 (Peninsula Laboratories, Inc.) was 
infused at Sng/kg/min. Measurements m baseline vs. 2 hours of ET 
infusion. The TIVCC group was characterized by a significant decrease 
in CO compared to the Sham group. 
RVRiRUj 
(SVR-Systemi 
RU=resistance 
Sham.) 
CC 
%E l5!z6* !i!Et= 12%5t 
T .91+.27 2.2M.26+ 1.67f.29t 1.2&28*; 
31f2 74f8* 64*7t 101*15* 
Hk.07 1.67f.26* .69&15 1.58&22* 
c vascular resistance, vocals resistance, 
units, *= ~~0.05 vs baseline, t=p<o.O5 TIVCC vs. 
This study demonstrates that despite the significant baseline low CO 
and vasoconsaicted state, the potent systemic and renal 
vasoconstricting actions of ET are preserved in this low ANF model of 
HF. These studies suggest a potential role for rather than 
chronically reduced CO as a modulator of exogenous ET in heart failure. 
